The FDA announced a shortage of Horizant (gabapentin enacarbil; GlaxoSmithKline) 600mg extended-release tablets. Horizant is a prodrug of gabapentin that is indicated for postherpetic neuralgia and for moderate-to-severe primary restless legs syndrome in adults.

GlaxoSmithKline is currently experiencing a backorder situation. XenoPort will assume manufacturing and commercialization of Horizant from May 1, 2013. XenoPort anticipates the Horizant shortage to extend into June 2013.

Horizant is also available in 300mg extended-release tablets.

For more information call GlaxoSmithKline at (888) 825-5249 or XenoPort at (877) 936-6778.